We here consider the problem of comparing the variances of two normal populations.
Introduction
In biomedical studies, we encounter occasions to compare the variances in variables of interest across different conditions. Such occasions may be divided into two different situations.
The first situation is when we mainly focus on comparing the variances. For example, test-retest variabilities (TRV) of visual acuity measurements are compared across different degrees of optical defocus in Rosser et al. (2004) and across different methods of scoring in Bosch and Wall (1997) .
The second situation is when we mainly focus on the location parameters (e.g., mean), and we want to check the assumption about the variances in the statistical method for comparing them.
In many clinical trials with continuous outcomes, linear (mixed) models including t-test, ANOVA, and ANCOVA are used as the method of the primary analysis. Based on whether the variances are equal or not, we may change the statistical method (e.g., Student's t-test or Welch's t-test) because inappropriate choice of the method may lead to incorrect conclusions. See, for example, Welch (1938) and Glass et al. (1972) . Therefore, to choose the correct method is important.
However, for many clinical trials in this situation, the tests comparing the variances are known to have lower power than expected. See, for example, Markowski and Markowski (1990) and Wilcox (1995) . This may occur because the sample sizes are calculated for comparing location parameters, which reduces the power of the test for comparing variances.
For a general two-group comparison of parameters, Bayesian approaches have gained increasing attention for their potential superiority in decision making compared to conventional frequentist methods, because a Bayesian approach can borrow strength from the historical data. For example, with a binomial distribution B(ni, pi), Altham (1969) , Kawasaki and Miyaoka (2012b) , Zaslavsky (2013) , and Kawasaki et al. (2014) considered the posterior probability P r(p1 > p1 | Kawasaki and Miyaoka (2012a) and Doi (2016) considered P r(λ1 < λ2 | X1, X2). Kawasaki and Miyaoka (2012b) referred to these types of probabilities as Bayesian indexes. For both distributions, the Bayesian indexes were shown to be expressed by the hypergeometric series, and the relationship between the Bayesian indexes and the p-values of conventional frequentist tests were investigated.
X1, X2). For the Poisson distribution P o(λi),
In this paper, we consider the problem of comparing the variances of two normal populations.
F -test is most frequently used in this situation. To achieve a more effective decision than possible with the F -test by borrowing strength from the historical data, we propose a Bayesian index of superiority and equivalence for comparing the variances of two groups of normally distributed data.
The remainder of this paper is structured as follows. In section 2, we propose the Bayesian index of superiority for three situations, express these indexes by the hypergeometric series and the cumulative distribution functions of well-known distributions, and investigate their relationship with the p-values of the F -test. In section 3, we propose the Bayesian index of equivalence, which is also expressed by the hypergeometric series and the cumulative distributions functions.
In section 4, we present the results of a Monte Carlo simulation to investigate the properties of θe(∆) ≥ γ for several ∆ and γ values used in the Bayesian index of equivalence. In section 5, we apply the Bayesian indexes to analyses of real data from actual clinical trials. Finally, we offer concluding remarks and highlight the prospects of these indexes in section 6.
is the hypergeometric series, and (k)t = k(k + 1) · · · (k + t − 1) for t ∈ N and (k)0 = 1 is the Pochhammer symbol,
is the cumulative distribution function of the F distribution F (ν1, ν2), and
is the cumulative distribution function of the beta distribution Beta (a, b) , also known as the regularized incomplete beta function.
proof Let λi = 1/σ 2 i be the precision, then
Then, the following theorem holds. 
proof From (2) and (3),
Remark 2 For the prior distribution,
. Therefore, as stated in remark 1, the Bayesian index can be expressed by theorem 1 as
Then, the following theorem holds.
Theorem 3 If µ1 and µ2 are known and the prior distribution of σ
Since ν i is the prior effective sample size of Scaled-inv-χ 2 (νi, τ 2 i ) as defined in Morita et al. (2008) , theorem 3 can be interpreted as follows: the Bayesian index with prior effective sample size 0 for both groups is equal to (1 − p) of the one-sided F -test. Furthermore, with the prior Scaled-inv-
, the Bayesian index can be interpreted as equal to the F -test with the prior information of αi additional samples.
Case 2: µ1 and µ2 are Unknown
In this case, we consider two types of the prior distributions of (µi, σ 2 i ). In each type, we denote the likelihood of (µi, σ 2 i ) by L(µi, σ 2 i | xi). Furthermore, in the following, we denote the probability density function of the normal inverse gamma distribution NIG (µ0, k, α, β) for
2.3.1 Calculation of the Bayesian index of superiority for the scaled inverse χ 2 variance prior
We first suppose that the prior distribution of µi is non-informative, i.e., f (µi) ∝ 1, and
. Here, the posterior distribution of (µi, σ 2 i ) can be derived as
« ,
Therefore, the posterior distribution of (µi, σ
and the marginal posterior distribution of σ
Then, the Bayesian index can be expressed by theorem 1 as 
Theorem 4 If the prior distribution of µ i is non-informative, i.e., f (µi) ∝ 1, and that of σ 
proof From (4) and (5),
Remark 3 For the prior distribution,
. Therefore, the Bayesian index can be expressed by theorem 1 as
Calculation of the Bayesian index of superiority for the normal inverse gamma prior
We next suppose that the prior distribution is µi | σ
Then, the posterior distribution of (µi, σ 2 i ) is NIG (µni, kni, ani, bni) . Hence, the marginal posterior distribution of σ 2 i is Inv- Ga(ani, bni) . Therefore, the Bayesian index can be expressed from theorem 1 as
2.3.4 The relationship between the Bayesian index of superiority for the normal inverse gamma prior and the p-value of the one-sided F -test Then, the following theorem holds.
Theorem 6 If the prior distribution of (µi, σ 
proof From (6) and (5),
Remark 4 For the prior distribution,
As already shown in theorem 5, if the prior distribution of (µi, σ
Remark on the Prior Distribution
To utilize the historical data effectively, we here consider how to construct the prior distribution of (µ i, σ 2 i ). For i = 1, 2 and j = 1, · · · , n0,i, let the historical data x0,ij independently follow N (µi, σ 2 i ), and x0,i = (x0,i1, . . . , x0,in 0,i ) , and let
Here, for 0 ≤ α i ≤ 1, an example of the conditional power prior distribution, defined in Ibrahim and Chen (2000), is
wherex
Then, the prior distribution of (µi, σ 
Bayesian Index of Equivalence
Next, we propose the Bayesian index of equivalence for ∆ satisfying 1 < ∆ as follows:
Here, we compare ∆ and 1/∆ not to the ratio of the variances but rather to the ratio of the standard deviations. Then, the following theorem holds.
Theorem 7 If the (marginal) posterior distribution of σ
proof Since P r(σ1/σ2 = ∆) = 0,
Then, consider the posterior distribution of σ 2 1 /σ 2 2 = λ2/λ1, where λi = 1/σ 2 i is the precision for i = 1, 2. From theorem 3 in Doi (2016) or (2.10) in Price and Bonett (2000) ,
The rest of the proof follows from theorem 3 in Doi (2016) .
Simulation
We conducted a Monte Carlo simulation to investigate the property of "θe ( we take γ = 0.90, 0.95 and ∆ = 1.10, 1.25, 1.50, 2.00. We conducted 100,000 iterations for each scenario. For the first scenario, we set σ1 = σ2 = 10; that is, the variances are equal. As shown in Table 1 , the percentage satisfying this condition heavily depended on the sample size. For the second scenario, we set σ1 = 15 and σ2 = 10; that is, σ1/σ2 = 1.5, so that the variances of group 1 are greater than those of group 2. As shown in Table 2 , the percentages satisfying θe(1.50) ≥ 0.90 and θe(1.50) ≥ 0.95 show minimal dependence on the sample size when n ≥ 50. These results suggest that the decision of suitable values of ∆ and γ must be considered depending on the 
Application
The application of the Bayesian indexes of superiority and equivalence was evaluated using data from actual clinical trials, as shown in Table 3 . Trial (a) and (b) are two selected trials shown in Table 1 of Gould (1991) . Here, we supposed that trial (a) is a previous trial and trial (b) is the present trial, and i = 1, 2 indicate the placebo and drug A group, respectively. Therefore, we utilized the data of trial (a) to specify the conditional power prior. We suppose that α = α1 = α2, and take α = 0.0, 0.2, 0.5, 0.8, 1.0. The prior distributions of (µi, σ 2 i ) were derived from (7) Table 4 . Prior distributions of (µ i , σ (3.04, 9.4, 4.2, 389.34) NIG(8.43, 8.8, 3.9, 287.02) 0.5 NIG(3.04, 23.5, 11.3, 973.36) NIG(8.43, 22.0, 10.5, 717.55) 0.8 NIG(3.04, 37.6, 18.3, 1557 .38) NIG(8.43, 35.2, 17.1, 1148 .08) 1.0 NIG(3.04, 47.0, 23.0, 1946 .72) NIG(8.43, 44.0, 21.5, 1435 .10) Table 5 . Posterior distributions of (µ i , σ (3.75, 53.0, 26.0, 1299 .61) NIG(10.20, 54.0, 26.5, 2336 .56) 0.2 NIG(3.64, 62.4, 30.7, 1692 .98) NIG(9.95, 62.8, 30.9, 2647 .29) 0.5 NIG(3.53, 76.5, 37.8, 2281 .18) NIG(9.69, 76.0, 37.5, 3103.08) 0.8 NIG(3.46, 90.6, 44.8, 2868 .62) α -Ga(26.0, 1299 .61) Inv-Ga(26.5, 2336 .56) 0.2 Inv-Ga(30.7, 1692 .98) Inv-Ga(30.9, 2647 .29) 0.5 Inv-Ga(37.8, 2281 .18) Inv-Ga(37.5, 3103.08) 0.8 Inv-Ga(44.8, 2868 we derived the posterior distributions. The posterior distributions of (µi, σ 2 i ) and the marginal posterior distributions of σ 2 i are shown in Table 5 and Table 6 , respectively. Finally, the Bayesian indexes are shown in Table 7 . For trial (a), the placebo group (i = 1) showed a larger standard deviation than the drug A group (i = 2). By contrast, for trial (b), the drug A group showed a larger standard deviation. According to the present data (trial (b)) only, that is, when α = 0, θ is quite small, which makes the variance of the placebo group seem greater. However, as α increases, i.e., the weight of the information of trial (a) increases, θ increases monotonically, and is no longer small. Furthermore, the p-value of the F -test with H0 : σ shows the equivalence, because the sample size is about 50 for both groups and for both the historical and present data. Then, when using only the present data (α = 0.0) and α = 0.2, the equivalence is not shown. By contrast, when α = 0.5, 0.8, 1.0, that is, when the weight of the historical data is moderate to large, the equivalence is shown.
In order to apply these indexes to the real clinical trials, we have to consider whether α, ∆ and γ can be pre-specified based on sufficiently reliable information. If we can pre-specify them suitably, we can determine the statistical method for comparing the means based on whether θe(∆) ≥ γ holds or not. On the other hand, if we cannot pre-specify them, it may be hard to determine the statistical method for comparing the means based on whether θe(∆) ≥ γ or not because it depends on the choice of α, ∆ and γ. In such case, we have to determine the statistical method based only on the present trial data, and we can utilize θe(∆)'s for several α's to scrutinize the appropriateness of the method. Depending on the values of θe(∆)'s, we may conduct sensitivity analysis by changing the statistical method for comparing the means.
Conclusion
We have proposed the Bayesian index of superiority to make a more efficient decision for comparing the variances between two groups than possible with the conventional F -test. This index was expressed by the hypergeometric series and the cumulative distribution functions of well-known distributions. Furthermore, we showed that as the amount of prior information decreases, the Bayesian index of superiority approaches the (1 − p) value of the F -test with −1 for i = 1, 2, then θ = 1 − p holds. This indicates that the Bayesian index with a "noninformative" prior or "zero prior effective sample size" can have the same statistical properties as the F -test; however, with incorporation of suitable historical data, the Bayesian index can potentially be used to make a more efficient decision. In addition, we proposed the Bayesian index of equivalence θe(∆), which was evaluated with a Monte Carlo simulation. The results showed that the percentage satisfying θe(∆) ≥ γ heavily depends on the sample size. Therefore, the appropriate values of ∆ and γ must be decided on a case-by-case basis. If we mainly focus on comparing the variances, we can utilize the index of superiority and equivalence based on the objectives of trials. If we want to check the assumption about the variances in some statistical method, we can utilize the index of equivalence. In any case, in order to use these indexes for the confirmatory purpose, it is crucial to pre-specify α1, α2, ∆, and γ suitably based on the sufficiently reliable information because θ and whether θe(∆) ≥ γ or not depend on them. Therefore, the important future work is to develop a suitable method for constructing the prior distributions, including selecting suitable historical data, and deciding α1, α2 for the conditional power prior.
